Summary: Skadden has moved back into the top spot for mergers and acquisitions in 2014 after finishing seventh in 2013. Skadden, Arps, Slate,...
In a cash-and-stock deal valued at $45.7 billion, Valeant Pharmaceuticals Inc. would give Allergan investors $48.30 in cash and 0.83 percent in...